ProBiotix Health with new CEO

ProBiotix Health, a life sciences company developing clinically proven probiotic solutions to tackle chronic lifestyle diseases like high cholesterol, high blood pressure and atherosclerosis, has appointed Steen Andersen as Chief Executive Officer.

The company expects his experience in the Probiotics industry to help build ProBiotix’s business in its next phase of growth, as it moves from selling ingredients to high value turnkey solutions.

Steen will join the Company after completing his notice period with his current employer. This appointment is part of a long-planned strategy to appoint an experienced industry business leader to the Company to drive sales and profitability, leaving the current acting CEO to focus on finding and developing new technologies that will provide the pipeline of new products and applications to ensure future growth.

The global Probiotics market is forecast to reach $94.48 billion by 2027, at a CAGR of 7.9%, dominated by the use of probiotics in food and beverages, particularly dairy, and using clinically proven probiotics as a natural replacement for pharmaceutical solutions (Fortune Business insights, 2022), the company said in the press release.

Stephen O’Hara, CEO of ProBiotix, commented:  ” Steen’s industry reputation , network of contacts, experience and track record of growing sales and profitability will help accelerate the growth and recognition of ProBiotix Health in its next phase of evolution.  Having established international sales and brand awareness of its award winning LPLDL® probiotic as an ingredient, the Company is now investing in building a presence in the dairy industry, extending the range of applications for LPLDL® into other areas of health, and increasing access to the USA and Asian markets.  The appointment of an industry leader to ProBiotix shows the confidence the board has in the Company’s products and opportunities in this rapidly growing area of health care.”